替吉奥联合奥沙利铂治疗可切除结直肠癌的临床效果及其与组织Cyclin E、Ki67蛋白表达的关系-现代医学

替吉奥联合奥沙利铂治疗可切除结直肠癌的临床效果及其与组织Cyclin E、Ki67蛋白表达的关系

单位：武汉市第八医院肛肠外科, 湖北武汉 430010

分类号：R735.3

出版年·卷·期（页码）：2017·36·第十一期（1650-1653）

摘要：

目的：研究替吉奥联合奥沙利铂治疗可切除结直肠癌的临床效果及其与组织Cyclin E、Ki67蛋白表达的关系。方法：共纳入124例采用根治性肿瘤切除术患者，随机将患者分为对照组和观察组（各62例）。对照组采用FOLFOX4化疗方案，观察组采用替吉奥联合奥沙利铂；随访12个月，比较化疗和手术效果；采用免疫组化染色比较肿瘤组织Cyclin E和Ki67蛋白表达。结果：化疗后，与对照组比，观察组化疗后肿瘤最大直径明显减少，有效率明显升高，手术根治率和切缘阴性率明显增高，复发率降低，总生存率提高，切除肿瘤组织的Cyclin E和Ki67蛋白表达明显降低（P<0.05），两组化疗并发症Ⅲ~Ⅳ级的发生率比较差异无统计学意义（P>0.05）。结论：替吉奥联合奥沙利铂可明显提高可切除结直肠癌的化疗和手术效果，改善生存预后，可能与降低组织Cyclin E及Ki67蛋白的表达有关。

Objective:To study the clinical effects of tegafur combined with oxaliplatin for patients with resectable colorectal cancer and the effect on Cyclin E and Ki67 proteins expressions. Methods:A total of 124 cases resectable colorectal cancer patients were enrolled and divided randomly into control(n=62) and observation(n=62) groups. All patients received radical resection after chemotherapy. The patients in the control group received FOLFOX4, and the observation group adopted tegafur combined with oxaliplatin. The effects of chemotherapy and operation were recorded and compared after 12 months between the two groups. The Cyclin E and Ki67 proteins were defined by immunohistochemistry. Results:After chemotherapy, the maximum diameter of tumor had significantly decreased, response rate had increased, the radical rate of tumor and negative rate of margin had increased, progression free survival had increased, recurrence rate had decreased, and the overall survival had increased in the observation group(P<0.05). While the occurrence of complications of Ⅲ-Ⅳ after chemotherapy in the two groups were not statistically different(P>0.05). Conclusion:Tegafur combined with oxaliplatin can greatly improve chemotherapy plus operation effects and survival prognosis, which may be related to the lowering Cyclin E and Ki67 protein expression in tumor.

参考文献：

[1] 张钊,刘胜利.KRAS基因突变与结直肠癌研究进展[J].东南大学学报(医学版),2016,35(1):154-157.
[2] XIE Q,WEN F,WEI Y Q,et al.Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon cancer[J].Colorectal Dis,2013,15(8):958-962.
[3] BERRETTA M,di FRANCIA R.Co mment on "Tegafur gimeracil oter combined with oxaliplatin for advanced colorectal cancer" is it cost effectiveness?[J].Eur Rev Med Pharmacol Sci,2016,20(1):5-6.
[4] 杨艳,韦淑贞,杜云翔,等.p53、Ki-67、PCNA的表达与食管鳞癌放疗近期疗效及预后的关系[J].东南大学学报(医学版),2017,36(2):155-161.
[5] LI W,ZHANG G,WANG H L,et al.Analysis of expression of cyclin E,p27kip1 and Ki67 protein in colorectal cancer tissues and its value for diagnosis,treatment and prognosis of disease[J].Eur Rev Med Pharmacol Sci,2016,20(23):4874-4879.
[6] YEH Y S,TSAI H L,HUANG C W,et al.Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage Ⅲ colon cancer after radical resection:study protocol for a randomized controlled trial[J].Trials,2017,18(1):191.
[7] HUANG W Y,HO C L,LEE C C,et al.Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage Ⅲ colon cancer[J].PLoS One,2017,12(3):e0174280.
[8] SUZUKI T,SADAHIRO S,TANAKA A,et al.Biopsy specimens obtained 7 days after starting chemoradiotherapy (CRT) provide reliable predictors of response to CRT for rectal cancer[J].Int J Radiat Oncol Biol Phys,2013,85(5):1232-1238.
[9] GUO B,LI L,GUO J,et al.M2 tumor-associated macrophages produce interleukin-17 to suppress oxaliplatin-induced apoptosis in hepatocellular carcinoma[J].Oncotarget,2017,8(27):44465-44476.
[10] 张庚,李伟,姜国胜.结肠镜取组织联合检测Cyclin E、p27kipl和Ki67的表达在结直肠癌中的临床意义[J].河北医药,2012,34(20):3077-3079.
[11] YANG Y,LI J,JIN L,et al.Independent correlation between Ki67 index and circulating tumor cells in the diagnosis of colorectal cancer[J].Anticancer Res,2017,37(8):4693-4700.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录